BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23147510)

  • 1. Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
    Dowjat K; Adayev T; Kaczmarski W; Wegiel J; Hwang YW
    J Neuropathol Exp Neurol; 2012 Dec; 71(12):1100-12. PubMed ID: 23147510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
    Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
    Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
    Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.
    Toiber D; Azkona G; Ben-Ari S; Torán N; Soreq H; Dierssen M
    Neurobiol Dis; 2010 Oct; 40(1):348-59. PubMed ID: 20600907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
    Dowjat K; Adayev T; Wojda U; Brzozowska K; Barczak A; Gabryelewicz T; Hwang YW
    J Alzheimers Dis; 2019; 72(4):1059-1075. PubMed ID: 31683476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
    Marechal D; Brault V; Leon A; Martin D; Lopes Pereira P; Loaëc N; Birling MC; Friocourt G; Blondel M; Herault Y
    Hum Mol Genet; 2019 May; 28(9):1561-1577. PubMed ID: 30649339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
    Çağlayan ES
    Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
    García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
    PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A).
    Kaczmarski W; Barua M; Mazur-Kolecka B; Frackowiak J; Dowjat W; Mehta P; Bolton D; Hwang YW; Rabe A; Albertini G; Wegiel J
    J Neurosci Res; 2014 Feb; 92(2):162-73. PubMed ID: 24327345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
    Hijazi M; Fillat C; Medina JM; Velasco A
    Exp Neurol; 2013 Jan; 239():229-34. PubMed ID: 23124096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome.
    Canzonetta C; Mulligan C; Deutsch S; Ruf S; O'Doherty A; Lyle R; Borel C; Lin-Marq N; Delom F; Groet J; Schnappauf F; De Vita S; Averill S; Priestley JV; Martin JE; Shipley J; Denyer G; Epstein CJ; Fillat C; Estivill X; Tybulewicz VL; Fisher EM; Antonarakis SE; Nizetic D
    Am J Hum Genet; 2008 Sep; 83(3):388-400. PubMed ID: 18771760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
    Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model.
    Hawley LE; Stringer M; Deal AJ; Folz A; Goodlett CR; Roper RJ
    Neurobiol Dis; 2024 Jan; 190():106359. PubMed ID: 37992782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development.
    Hämmerle B; Elizalde C; Tejedor FJ
    Eur J Neurosci; 2008 Mar; 27(5):1061-74. PubMed ID: 18364031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular Mechanism Underlying Abnormal Differentiation of Neural Progenitor Cells in the Developing Down Syndrome Brain].
    Kurabayashi N; Sanada K
    Yakugaku Zasshi; 2017; 137(7):795-800. PubMed ID: 28674289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.
    Laguna A; Barallobre MJ; Marchena MÁ; Mateus C; Ramírez E; Martínez-Cue C; Delabar JM; Castelo-Branco M; de la Villa P; Arbonés ML
    Hum Mol Genet; 2013 Jul; 22(14):2775-84. PubMed ID: 23512985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons.
    Martinez de Lagran M; Benavides-Piccione R; Ballesteros-Yañez I; Calvo M; Morales M; Fillat C; Defelipe J; Ramakers GJ; Dierssen M
    Cereb Cortex; 2012 Dec; 22(12):2867-77. PubMed ID: 22215728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.